secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001104659-22-091222
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Q2 net loss $10.6M; cash $30M; CF topline data expected Q3 2022
---------------------------------------------------------------------

- Q2 2022 net loss $10.6M ($0.12/sh) vs $36.1M ($0.54/sh) in Q2 2021; prior year included $22.7M Zikani acquisition expense.
- Cash and equivalents $30.0M as of June 30, 2022; sufficient to fund operations into Q4 2023; in compliance with debt covenants.
- CF Phase 2 expansion arms top-line results expected by end of Q3 2022; inhaled delivery IND on track for Q4 2022.
- Alport syndrome proof-of-concept trial to start H2 2022 in up to 8 patients; topline results expected H1 2023.
- ZKN-013 repeat study confirms potential in FAP model; IND for FAP expected H2 2023; RDEB IND on track for Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465922091222/0001104659-22-091222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465922091222/tm2223461d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-091222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer